Ab Kabi

Kabi Ab

Lars-Olov Andersson

Erik Yngve Holmer

Gudrun M Einarsson

Gunnar Hanshoff

John Y Thunberg

Gudrun E Backstrom

Ulf P Lindahl

Inga H Sandberg

Nanna Forsman

Lennart P Kaplan

Goran Lindroos

Maggie Miller-Andersson

Lars-Ake Fransson

Hakan G Borg

Hakan Gunnar Borg

Elisabeth Charlotte Carling Nee Ehrenberg

Ewa G Soderstrom

Heparin fragments having selective anticoagulation activity having 14-18 sugar units, the disaccharide unit L-iduronosyl-2-O-sulphate-N-sulpho-U-glucosamine-6-O-sulphate being the main component, and where unsulphated L-iduronic acid is in a position situated 3-5 sugar units from the unreducing terminal. Pharmaceutical compositions containing such heparin fragments. Processes for the preparation of the heparin fragments.

Heparin fragments having selective anticoagulation activity

Hepatitis virus is removed from a biological material contaminated with the virus by contact with a preparation. The preparation may be agarose gel or beaded polyacrylamide plastic coupled with a variety of hydrophobic ligands.

Method of removal of hepatitis virus

Hepatitis B virus (detectable as its surface antigen HB.sub.s Ag) is produced in a purification preferably suitable for use in preparing a hepatitis vaccine, by contacting a crude biological starting material containing hepatitis B virus with a water-insoluble cross-linked sulfated polysaccharide gel matrix adsorbing agent to adsorb the hepatitis B virus thereon and then desorbing that virus therefrom by treating that hepatitis B virus carrying adsorbent with a desorbing agent.

Purifying and isolating method for hepatitis virus to use in preparing

Crude clinically used heparin preparations having a low specific activity, for example, about 130 heparin units per milligram are purified by contacting such liquid crude heparin preparations with a gel matrix complexed with (i.e. having linked to it) antithrombin or inter-alpha-trypsin inhibitor as a heparin-binding plasma protein, and then desorbing or eluting the heparin from the antithrombin or inter-alpha-trypsin inhibitor complexed gel matrix as with an applicable buffer, removing any salt in the solution with the heparin by gel filtration and then drying the heparin as by lyophilization.

Heparin purification method

The blood coagulation factors I (fibrinogen) and VIII (antihemophilia factor, abbreviated AHF) are isolated in high yields from animal tissue materials such as blood or blood products (e.g. plasma) or plasma fractions by a procedure involving the essential step of adsorption (as in affinity chromatography) of at least one of these factors, in a liquid system, onto a water-insoluble gel matrix primarily composed of a cross-linked sulfated or sulfonated, gel-forming carbohydrate such as cross-linked dextran sulfate-agarose, cross-linked dextran sulfate-dextran, cross-linked heparin-agarose and other such gel matrix-providing substances.

Isolation of coagulation factors I and VIII from biological material

Growing community of inventors

Knivsta, Sweden

Lars-Olov Andersson